Skip to content

The Economic Burden of Chronic Obstructive Pulmonary Disease(COPD) in South Korea

The Economic Burden of Patients With COPD in South Korea

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02750189
Acronym
BOC
Enrollment
390
Registered
2016-04-25
Start date
2015-09-30
Completion date
2017-01-31
Last updated
2017-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease, COPD

Brief summary

The purpose of this study is to estimate a direct/indirect medical cost and to provide evidence establishing efficient strategies to reduce medical costs of COPD in Korea.

Detailed description

This study is a multi-center research on economic burdens of COPD for a year. It is composed of three phases detailed as follow. Phase 1: Direct Cost Estimation in COPD patients (N = 400) Direct cost determined as amount of money expended to medical institutes for treatment. Estimated costs, based on the information from Health insurance review agency(HIRA) and The National Health and Nutrition Examination Survey (NHANES) data, are collected. Phase 2: Indirect cost Estimation by Sampling Survey in COPD patient Indirect cost is extra-expanses excluding hospital fees, including cost for transportation, medical instruments, home care services and loss of labor capacity reduction. The information was collected by structured questionnaire for 12 weeks. Phase 3: Direct/Indirect cost is validated and analyzed based on the collected information from phase 1 and 2 according to severity defined by the GOLD guideline.

Interventions

Money spent to treat COPD in medical institute based on HIRA

OTHERIndirect cost

extra-expanses excluding hospital fees

Sponsors

GlaxoSmithKline
CollaboratorINDUSTRY
Konkuk University Medical Center
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Over 20 years old * COPD patients

Exclusion criteria

* Patients who disagree with participating in research

Design outcomes

Primary

MeasureTime frameDescription
Total cost of COPD1 yearKorean won, KRW

Secondary

MeasureTime frameDescription
The cost of alternative medication usethree monthsWe will add up the costs of herbal medicine, health supplement, medical equipments and respiratory rehabilitation. According to patients, the items of alternative medication use would be different.
Cost of productivity lostLast 7days from filling out questionnairesReduction of working hour and monthly income for being late or abscence from work.
The number of acute exacerbations1 yearNumber of events
The total number of visits1 yearprimary clinics, emergency department and hospital admission.
Nursing cost1 year (past 1 year before filling questionnaires)payment for nurse (Korean won, KRW)
EuroQol five dimension(EQ-5D)3 monthsMeasured by questionnaire based by EQ -5D ( EQ-5D essentially consists of 2 pages - the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS) . The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems )

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026